Patient & Survivor Care
Conference Coverage
Cancer drug shortages spur worry, rationing, and tough choices
Limited supplies of crucial medications are disrupting patient care, oncologists say.
Conference Coverage
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
A pair of new studies show that drugs can reduce cancer risk when cells are elusive.
Conference Coverage
New study backs up capecitabine dosing practice in metastatic BC
Study finds similar progression-free and overall survival in 7-day-on/7-day-off schedule, with fewer side effects than 14 days on, 7 days off.
Conference Coverage
Breast cancer experts and other HCPs disagree on treatment strategies for early BC
It’s challenging for some oncologists to keep up with the nuances of a rapidly changing field, said the author of new research.
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
From the Journals
Cognitive decline risk in adult childhood cancer survivors
“We need to educate oncologists and primary care providers on the risks our survivors face long after completion of therapy.”
Conference Coverage
ER+/HER2– breast cancer: Is first or second line CDK4/6 inhibitor therapy better?
New study challenges the need for using CDK4/6 inhibitors as first line treatment, according to author.
From the Journals
Ovarian cancer: Sequencing strategy identifies biomarker that could guide treatment
Novel sequencing strategy appears to be a reliable predictor of homologous recombination DNA repair deficiency.
Conference Coverage
Metronomic chemotherapy performs well in second-line head and neck cancer
Lower-dose therapy granted PFS and OS gains, with fewer side effects, compared with standard chemotherapy options.
Conference Coverage
Antibody-drug conjugate changes standard of care for platinum-resistant ovarian cancer
A novel therapy has a favorable safety profile, and more like it may be on the way.
Conference Coverage
Oral drug for brain tumor could change treatment landscape
Vorasidenib was associated with a significant delay in time to disease progression when compared with placebo, in a new study.